跳至主要内容
临床试验/CTRI/2025/10/096147
CTRI/2025/10/096147招募中不适用

Assessment of patient satisfaction ease of training and clinical effectiveness of ICS-LABA combinations delivered through Ciphaler A real world observational study in patients with asthma CONTROL STUDY

Cipla Ltd3 个研究点 分布在 1 个国家目标入组 2,500 人开始时间: 2025年11月5日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
Cipla Ltd
入组人数
2,500
试验地点
3
主要终点
Patient satisfaction

研究概览

简要总结

Drugs administered through the inhaled route have become very important for the treatment of respiratory diseases like asthma. This is a real-world, observational study to assess patient satisfaction, ease of training and clinical effectiveness of ICS-LABA combinations delivered through Ciphaler® in patients with asthma.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • 1 Either gender, of age 18 years or above, with documented diagnosis of Asthma (as per GINA 2025) 2 Prescribed treatment with ICS-LABA delivered through the Ciphaler® based on investigator discretion 3 Willing for follow-up at scheduled visit as per protocol 4 A voluntarily given written, signed, dated informed consent from participants and/or legally acceptable representative.

排除标准

  • 1 Hypersensitivity to the study drug or any of its components 2 Life-threatening or unstable respiratory disease, including lower respiratory tract infection, within the past 4 weeks from screening 3 Acute episodes of asthma requiring systemic corticosteroids, emergency care or hospitalization in the 30 days prior to Baseline visit 4 Chronic pulmonary diseases other than asthma such as COPD, post-tuberculosis lung disease, pulmonary fibrotic disease, or pulmonary arterial hypertension 5 Severe asthma patients receiving biologicals.

结局指标

主要结局

Patient satisfaction

时间窗: 8 weeks

次要结局

  • 1. Ease of training with Ciphaler®
  • 2. Change in ACQ-5 score(Baseline)
  • 3. Change in ACQ-5 score categories as well controlled (ACQ-5 less than 0.75), partially controlled (ACQ-5 more than 0.75 to less than 1.5), and uncontrolled (ACQ-5 more than 1.5)(Baseline)
  • 4. Adverse Event(Through Study)

研究者

发起方
Cipla Ltd
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Sundeep Salvi

Chest Research and Training Private Limited

研究点 (3)

Loading locations...

相似试验